Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 5.568
Filtrer
1.
Sci Rep ; 14(1): 13980, 2024 06 17.
Article de Anglais | MEDLINE | ID: mdl-38886484

RÉSUMÉ

Maraviroc (MVC) is an antiretroviral drug capable of binding to CCR5 receptors and block HIV entry into target cells. Moreover, MVC can activate NF-kB pathway and induce viral transcription in HIV-infected cells, being proposed as a latency reversal agent (LRA) in HIV cure strategies. However, the evaluation of immunological and metabolic parameters induced by MVC concentrations capable of inducing HIV transcription have not been explored in depth. We cultured isolated CD4 T cells in the absence or presence of MVC, and evaluated the frequency of CD4 T cell subpopulations and activation markers levels by flow cytometry, and the oxidative and glycolytic metabolic rates of CD4 T cells using a Seahorse Analyzer. Our results indicate that a high concentration of MVC did not increase the levels of activation markers, as well as glycolytic or oxidative metabolic rates in CD4 T cells. Furthermore, MVC did not induce significant changes in the frequency and activation levels of memory cell subpopulations. Our data support a safety profile of MVC as a promising LRA candidate since it does not induce alterations of the immunological and metabolic parameters that could affect the functionality of these immune cells.


Sujet(s)
Lymphocytes T CD4+ , Maraviroc , Maraviroc/pharmacologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Lymphocytes T CD4+/immunologie , Humains , Glycolyse/effets des médicaments et des substances chimiques , Infections à VIH/traitement médicamenteux , Infections à VIH/métabolisme , Infections à VIH/immunologie , Cellules cultivées , Triazoles/pharmacologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/effets des médicaments et des substances chimiques , Activation des lymphocytes/effets des médicaments et des substances chimiques , Mâle , Antagonistes des récepteurs CCR5/pharmacologie , Cyclohexanes/pharmacologie , Adulte
2.
Cells ; 13(11)2024 May 21.
Article de Anglais | MEDLINE | ID: mdl-38891019

RÉSUMÉ

The risk of developing pulmonary hypertension (PH) in people living with HIV is at least 300-fold higher than in the general population, and illicit drug use further potentiates the development of HIV-associated PH. The relevance of extracellular vesicles (EVs) containing both coding as well as non-coding RNAs in PH secondary to HIV infection and drug abuse is yet to be explored. We here compared the miRNA cargo of plasma-derived EVs from HIV-infected stimulant users with (HIV + Stimulants + PH) and without PH (HIV + Stimulants) using small RNA sequencing. The data were compared with 12 PH datasets available in the GEO database to identify potential candidate gene targets for differentially altered miRNAs using the following functional analysis tools: ingenuity pathway analysis (IPA), over-representation analysis (ORA), and gene set enrichment analysis (GSEA). MiRNAs involved in promoting cell proliferation and inhibition of intrinsic apoptotic signaling pathways were among the top upregulated miRNAs identified in EVs from the HIV + Stimulants + PH group compared to the HIV + Stimulants group. Alternatively, the downregulated miRNAs in the HIV + Stimulants + PH group suggested an association with the negative regulation of smooth muscle cell proliferation, IL-2 mediated signaling, and transmembrane receptor protein tyrosine kinase signaling pathways. The validation of significantly differentially expressed miRNAs in an independent set of HIV-infected (cocaine users and nondrug users) with and without PH confirmed the upregulation of miR-32-5p, 92-b-3p, and 301a-3p positively regulating cellular proliferation and downregulation of miR-5571, -4670 negatively regulating smooth muscle proliferation in EVs from HIV-PH patients. This increase in miR-301a-3p and decrease in miR-4670 were negatively correlated with the CD4 count and FEV1/FVC ratio, and positively correlated with viral load. Collectively, this data suggest the association of alterations in the miRNA cargo of circulating EVs with HIV-PH.


Sujet(s)
Vésicules extracellulaires , Infections à VIH , Hypertension pulmonaire , microARN , Humains , Vésicules extracellulaires/métabolisme , Infections à VIH/complications , Infections à VIH/sang , Infections à VIH/métabolisme , Hypertension pulmonaire/génétique , Hypertension pulmonaire/métabolisme , microARN/génétique , microARN/métabolisme , microARN/sang , Mâle , Femelle , Adulte , Adulte d'âge moyen , Prolifération cellulaire
3.
PLoS Pathog ; 20(6): e1012281, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38848441

RÉSUMÉ

Understanding the mechanisms that drive HIV expression and latency is a key goal for achieving an HIV cure. Here we investigate the role of the SETD2 histone methyltransferase, which deposits H3K36 trimethylation (H3K36me3), in HIV infection. We show that prevention of H3K36me3 by a potent and selective inhibitor of SETD2 (EPZ-719) leads to reduced post-integration viral gene expression and accelerated emergence of latently infected cells. CRISPR/Cas9-mediated knockout of SETD2 in primary CD4 T cells confirmed the role of SETD2 in HIV expression. Transcriptomic profiling of EPZ-719-exposed HIV-infected cells identified numerous pathways impacted by EPZ-719. Notably, depletion of H3K36me3 prior to infection did not prevent HIV integration but resulted in a shift of integration sites from highly transcribed genes to quiescent chromatin regions and to polycomb repressed regions. We also observed that SETD2 inhibition did not apparently affect HIV RNA levels, indicating a post-transcriptional mechanism affecting HIV expression. Viral RNA splicing was modestly reduced in the presence of EPZ-719. Intriguingly, EPZ-719 exposure enhanced responsiveness of latent HIV to the HDAC inhibitor vorinostat, suggesting that H3K36me3 can contribute to a repressive chromatin state at the HIV locus. These results identify SETD2 and H3K36me3 as novel regulators of HIV integration, expression and latency.


Sujet(s)
Infections à VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Histone-lysine N-methyltransferase , Latence virale , Histone-lysine N-methyltransferase/métabolisme , Histone-lysine N-methyltransferase/génétique , Humains , Latence virale/physiologie , Infections à VIH/virologie , Infections à VIH/métabolisme , Infections à VIH/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Lymphocytes T CD4+/virologie , Lymphocytes T CD4+/métabolisme , Régulation de l'expression des gènes viraux
4.
Article de Anglais | MEDLINE | ID: mdl-38902848

RÉSUMÉ

Despite the success of antiretroviral therapy, human immunodeficiency virus (HIV) cannot be cured because of a reservoir of latently infected cells that evades therapy. To understand the mechanisms of HIV latency, we employed an integrated single-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin with sequencing (scATAC-seq) approach to simultaneously profile the transcriptomic and epigenomic characteristics of ∼ 125,000 latently infected primary CD4+ T cells after reactivation using three different latency reversing agents. Differentially expressed genes and differentially accessible motifs were used to examine transcriptional pathways and transcription factor (TF) activities across the cell population. We identified cellular transcripts and TFs whose expression/activity was correlated with viral reactivation and demonstrated that a machine learning model trained on these data was 75%-79% accurate at predicting viral reactivation. Finally, we validated the role of two candidate HIV-regulating factors, FOXP1 and GATA3, in viral transcription. These data demonstrate the power of integrated multimodal single-cell analysis to uncover novel relationships between host cell factors and HIV latency.


Sujet(s)
Lymphocytes T CD4+ , Facteur de transcription GATA-3 , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Analyse sur cellule unique , Activation virale , Latence virale , Latence virale/génétique , Humains , Activation virale/génétique , Analyse sur cellule unique/méthodes , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Lymphocytes T CD4+/virologie , Lymphocytes T CD4+/métabolisme , Facteur de transcription GATA-3/métabolisme , Facteur de transcription GATA-3/génétique , Facteurs de transcription Forkhead/métabolisme , Facteurs de transcription Forkhead/génétique , Infections à VIH/virologie , Infections à VIH/génétique , Infections à VIH/métabolisme , Protéines de répression/métabolisme , Protéines de répression/génétique , Transcriptome/génétique , Régulation de l'expression des gènes viraux
5.
Nat Commun ; 15(1): 5290, 2024 Jun 21.
Article de Anglais | MEDLINE | ID: mdl-38906865

RÉSUMÉ

Long-term non-progressors (LTNPs) of HIV-1 infection may provide important insights into mechanisms involved in viral control and pathogenesis. Here, our results suggest that the ribosomal protein lateral stalk subunit P1 (RPLP1) is expressed at higher levels in LTNPs compared to regular progressors (RPs). Functionally, RPLP1 inhibits transcription of clade B HIV-1 strains by occupying the C/EBPß binding sites in the viral long terminal repeat (LTR). This interaction requires the α-helixes 2 and 4 domains of RPLP1 and is evaded by HIV-1 group M subtype C and group N, O and P strains that do not require C/EBPß for transcription. We further demonstrate that HIV-1-induced translocation of RPLP1 from the cytoplasm to the nucleus is essential for antiviral activity. Finally, knock-down of RPLP1 promotes reactivation of latent HIV-1 proviruses. Thus, RPLP1 may play a role in the maintenance of HIV-1 latency and resistance to RPLP1 restriction may contribute to the effective spread of clade C HIV-1 strains.


Sujet(s)
Protéine bêta de liaison aux séquences stimulatrices de type CCAAT , Infections à VIH , Répétition terminale longue du VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Protéines ribosomiques , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/métabolisme , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Humains , Protéines ribosomiques/métabolisme , Protéines ribosomiques/génétique , Répétition terminale longue du VIH/génétique , Protéine bêta de liaison aux séquences stimulatrices de type CCAAT/métabolisme , Protéine bêta de liaison aux séquences stimulatrices de type CCAAT/génétique , Infections à VIH/virologie , Infections à VIH/métabolisme , Infections à VIH/génétique , Transcription génétique , Liaison aux protéines , Latence virale/génétique , Sites de fixation , Régulation de l'expression des gènes viraux , Cellules HEK293 , Noyau de la cellule/métabolisme
6.
Sci Rep ; 14(1): 12974, 2024 06 05.
Article de Anglais | MEDLINE | ID: mdl-38839923

RÉSUMÉ

Programmed death-ligand 1 (PD-L1) is overexpressed in squamous cervical cancer (SCC) and can be used for targeted immunotherapy. The highest mortality rates of SCC are reported in sub-Saharan Africa, where Human immunodeficiency virus (HIV) prevalence is high. In Mozambique most SCC patients present at advanced stages. Thus, there is a need to introduce new treatment options. However, immunocompromised patients were frequently excluded in previous clinical trials. Our aim was to determine if PD-L1 expression in SCC is as prevalent among women living with HIV (WLWH) as among other patients. 575 SCC from Maputo Central Hospital were included. HIV status was available in 266 (46%) cases PD-L1 expression was scored through tumour proportion score (TPS) and combined positive score (CPS). PD-L1 was positive in 20.1% of the cases (n = 110), TPS (score ≥ 25%) and in 26.3% (n = 144), CPS (score ≥ 1). Stratifying according to the HIV status, WLWH were TPS positive in 16.7%, compared to 20.9%, p = 0.43, and concerning CPS 21.1% versus 28.7%, p = 0.19, respectively. PD-L1 status was not influenced by stage, Ki-67 or p16, CD8 expression influenced only CPS status. Our data indicates that the documented effect of PD-L1 therapy on SCC should be confirmed in randomized clinical trials in an HIV endemic milieu.


Sujet(s)
Antigène CD274 , Carcinome épidermoïde , Infections à VIH , Tumeurs du col de l'utérus , Humains , Femelle , Tumeurs du col de l'utérus/métabolisme , Tumeurs du col de l'utérus/anatomopathologie , Antigène CD274/métabolisme , Mozambique/épidémiologie , Infections à VIH/complications , Infections à VIH/métabolisme , Carcinome épidermoïde/métabolisme , Carcinome épidermoïde/anatomopathologie , Adulte d'âge moyen , Adulte , Sujet âgé
7.
Front Public Health ; 12: 1400332, 2024.
Article de Anglais | MEDLINE | ID: mdl-38912274

RÉSUMÉ

Background: The human immunodeficiency virus (HIV) remains a critical global health issue, with a pressing need for effective diagnostic and monitoring tools. Methodology: This study explored distinctions in salivary metabolome among healthy individuals, individuals with HIV, and those receiving highly active antiretroviral therapy (HAART). Utilizing LC-MS/MS for exhaustive metabolomics profiling, we analyzed 90 oral saliva samples from individuals with HIV, categorized by CD4 count levels in the peripheral blood. Results: Orthogonal partial least squares-discriminant analysis (OPLS-DA) and other analyses underscored significant metabolic alterations in individuals with HIV, especially in energy metabolism pathways. Notably, post-HAART metabolic profiles indicated a substantial presence of exogenous metabolites and changes in amino acid pathways like arginine, proline, and lysine degradation. Key metabolites such as citric acid, L-glutamic acid, and L-histidine were identified as potential indicators of disease progression or recovery. Differential metabolite selection and functional enrichment analysis, combined with receiver operating characteristic (ROC) and random forest analyses, pinpointed potential biomarkers for different stages of HIV infection. Additionally, our research examined the interplay between oral metabolites and microorganisms such as herpes simplex virus type 1 (HSV1), bacteria, and fungi in individuals with HIV, revealing crucial interactions. Conclusion: This investigation seeks to contribute understanding into the metabolic shifts occurring in HIV infection and following the initiation of HAART, while tentatively proposing novel avenues for diagnostic and treatment monitoring through salivary metabolomics.


Sujet(s)
Thérapie antirétrovirale hautement active , Marqueurs biologiques , Infections à VIH , Métabolome , Salive , Humains , Salive/métabolisme , Salive/composition chimique , Infections à VIH/métabolisme , Marqueurs biologiques/métabolisme , Mâle , Métabolome/physiologie , Adulte , Femelle , Adulte d'âge moyen , Chromatographie en phase liquide , Métabolomique , Spectrométrie de masse en tandem , Diagnostic précoce , Numération des lymphocytes CD4
8.
ACS Chem Biol ; 19(6): 1243-1249, 2024 Jun 21.
Article de Anglais | MEDLINE | ID: mdl-38747804

RÉSUMÉ

Nicotinamide adenine dinucleotide (NAD) is a critical component of the cellular metabolism and also serves as an alternative 5' cap on various RNAs. However, the function of the NAD RNA cap is still under investigation. We studied NAD capping of RNAs in HIV-1-infected cells because HIV-1 is responsible for the depletion of the NAD/NADH cellular pool and causing intracellular pellagra. By applying the NAD captureSeq protocol to HIV-1-infected and uninfected cells, we revealed that four snRNAs (e.g., U1) and four snoRNAs lost their NAD cap when infected with HIV-1. Here, we provide evidence that the presence of the NAD cap decreases the stability of the U1/HIV-1 pre-mRNA duplex. Additionally, we demonstrate that reducing the quantity of NAD-capped RNA by overexpressing the NAD RNA decapping enzyme DXO results in an increase in HIV-1 infectivity. This suggests that NAD capping is unfavorable for HIV-1 and plays a role in its infectivity.


Sujet(s)
Infections à VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , NAD , Petit ARN nucléaire , Petit ARN nucléolaire , Humains , NAD/métabolisme , Petit ARN nucléolaire/métabolisme , Petit ARN nucléolaire/génétique , Petit ARN nucléaire/métabolisme , Infections à VIH/virologie , Infections à VIH/métabolisme , Coiffes des ARN/métabolisme
9.
Int J Mol Sci ; 25(9)2024 Apr 26.
Article de Anglais | MEDLINE | ID: mdl-38731951

RÉSUMÉ

Distal sensory polyneuropathy (DSP) and distal neuropathic pain (DNP) remain significant challenges for older people with HIV (PWH), necessitating enhanced clinical attention. HIV and certain antiretroviral therapies (ARTs) can compromise mitochondrial function and impact mitochondrial DNA (mtDNA) replication, which is linked to DSP in ART-treated PWH. This study investigated mtDNA, mitochondrial fission and fusion proteins, and mitochondrial electron transport chain protein changes in the dorsal root ganglions (DRGs) and sural nerves (SuNs) of 11 autopsied PWH. In antemortem standardized assessments, six had no or one sign of DSP, while five exhibited two or more DSP signs. Digital droplet polymerase chain reaction was used to measure mtDNA quantity and the common deletions in isolated DNA. We found lower mtDNA copy numbers in DSP+ donors. SuNs exhibited a higher proportion of mtDNA common deletion than DRGs in both groups. Mitochondrial electron transport chain (ETC) proteins were altered in the DRGs of DSP+ compared to DSP- donors, particularly Complex I. These findings suggest that reduced mtDNA quantity and increased common deletion abundance may contribute to DSP in PWH, indicating diminished mitochondrial activity in the sensory neurons. Accumulated ETC proteins in the DRG imply impaired mitochondrial transport to the sensory neuron's distal portion. Identifying molecules to safeguard mitochondrial integrity could aid in treating or preventing HIV-associated peripheral neuropathy.


Sujet(s)
ADN mitochondrial , Infections à VIH , Humains , ADN mitochondrial/génétique , ADN mitochondrial/métabolisme , Mâle , Infections à VIH/métabolisme , Infections à VIH/virologie , Infections à VIH/génétique , Projets pilotes , Femelle , Adulte d'âge moyen , Sujet âgé , Ganglions sensitifs des nerfs spinaux/métabolisme , Ganglions sensitifs des nerfs spinaux/virologie , Mitochondries/métabolisme , Mitochondries/génétique , Complexe enzymatique de la chaine respiratoire mitochondriale/métabolisme , Complexe enzymatique de la chaine respiratoire mitochondriale/génétique , Nerfs périphériques/métabolisme , Nerfs périphériques/virologie , Nerfs périphériques/anatomopathologie , Adulte , Nerf sural/métabolisme , Nerf sural/anatomopathologie
10.
Biomolecules ; 14(5)2024 May 10.
Article de Anglais | MEDLINE | ID: mdl-38785977

RÉSUMÉ

Host restriction factor SERINC5 (SER5) incorporates into the HIV-1 membrane and inhibits infectivity by a poorly understood mechanism. Recently, SER5 was found to exhibit scramblase-like activity leading to the externalization of phosphatidylserine (PS) on the viral surface, which has been proposed to be responsible for SER5's antiviral activity. This and other reports that document modulation of HIV-1 infectivity by viral lipid composition prompted us to investigate the role of PS in regulating SER5-mediated HIV-1 restriction. First, we show that the level of SER5 incorporation into virions correlates with an increase in PS levels in the outer leaflet of the viral membrane. We developed an assay to estimate the PS distribution across the viral membrane and found that SER5, but not SER2, which lacks antiviral activity, abrogates PS asymmetry by externalizing this lipid. Second, SER5 incorporation diminished the infectivity of pseudoviruses produced from cells lacking a flippase subunit CDC50a and, therefore, exhibited a higher baseline level of surface-accessible PS. Finally, exogenous manipulation of the viral PS levels utilizing methyl-alpha-cyclodextrin revealed a lack of correlation between external PS and virion infectivity. Taken together, our study implies that the increased PS exposure to SER5-containing virions itself is not directly linked to HIV-1 restriction.


Sujet(s)
VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Protéines membranaires , Phosphatidylsérine , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/métabolisme , Phosphatidylsérine/métabolisme , Humains , Protéines membranaires/métabolisme , Virion/métabolisme , Cellules HEK293 , Membrane cellulaire/métabolisme , Infections à VIH/virologie , Infections à VIH/métabolisme
11.
Biol Pharm Bull ; 47(5): 905-911, 2024.
Article de Anglais | MEDLINE | ID: mdl-38692867

RÉSUMÉ

Viruses require host cells to replicate and proliferate, which indicates that viruses hijack the cellular machinery. Human immunodeficiency virus type 1 (HIV-1) primarily infects CD4-positive T cells, and efficiently uses cellular proteins to replicate. Cells already have proteins that inhibit the replication of the foreign HIV-1, but their function is suppressed by viral proteins. Intriguingly, HIV-1 infection also changes the cellular metabolism to aerobic glycolysis. This phenomenon has been interpreted as a cellular response to maintain homeostasis during viral infection, yet HIV-1 efficiently replicates even in this environment. In this review, we discuss the regulatory role of glycolytic enzymes in viral replication and the impact of aerobic glycolysis on viral infection by introducing various host proteins involved in viral replication. Furthermore, we would like to propose a "glyceraldehyde-3-phosphate dehydrogenase-induced shock (G-shock) and kill strategy" that maximizes the antiviral effect of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to eliminate latently HIV-1-infected cells.


Sujet(s)
Glycolyse , Infections à VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Réplication virale , Humains , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Glycolyse/physiologie , Infections à VIH/virologie , Infections à VIH/métabolisme , Infections à VIH/immunologie , Glyceraldehyde 3-phosphate dehydrogenases/métabolisme
12.
Methods Mol Biol ; 2807: 15-30, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743218

RÉSUMÉ

Live-cell imaging has become a powerful tool for dissecting the behavior of viral complexes during HIV-1 infection with high temporal and spatial resolution. Very few HIV-1 particles in a viral population are infectious and successfully complete replication (~1/50). Single-particle live-cell imaging enables the study of these rare infectious viral particles, which cannot be accomplished in biochemical assays that measure the average property of the entire viral population, most of which are not infectious. The timing and location of many events in the early stage of the HIV-1 life cycle, including nuclear import, uncoating, and integration, have only recently been elucidated. Live-cell imaging also provides a valuable approach to study interactions of viral and host factors in distinct cellular compartments and at specific stages of viral replication. Successful live-cell imaging experiments require careful consideration of the fluorescent labeling method used and avoid or minimize its potential impact on normal viral replication and produce misleading results. Ideally, it is beneficial to utilize multiple virus labeling strategies and compare the results to ensure that the virion labeling did not adversely influence the viral replication step that is under investigation. Another potential benefit of using different labeling strategies is that they can provide information about the state of the viral complexes. Here, we describe our methods that utilize multiple fluorescent protein labeling approaches to visualize and quantify important events in the HIV-1 life cycle, including docking HIV-1 particles with the nuclear envelope (NE) and their nuclear import, uncoating, and proviral transcription.


Sujet(s)
Transport nucléaire actif , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Transcription génétique , Réplication virale , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Humains , Décapsidation virale , Provirus/génétique , Provirus/physiologie , Noyau de la cellule/métabolisme , Noyau de la cellule/virologie , Infections à VIH/virologie , Infections à VIH/métabolisme , Virion/métabolisme , Virion/génétique
13.
Methods Mol Biol ; 2807: 77-91, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743222

RÉSUMÉ

HIV-1 virions incorporate viral RNA, cellular RNAs, and proteins during the assembly process. Some of these components, such as the viral RNA genome and viral proteins, are essential for viral replication, whereas others, such as host innate immune proteins, can inhibit virus replication. Therefore, analyzing the virion content is an integral part of studying HIV-1 replication. Traditionally, virion contents have been examined using biochemical assays, which can provide information on the presence or absence of the molecule of interest but not its distribution in the virion population. Here, we describe a method, single-virion analysis, that directly examines the presence of molecules of interest in individual viral particles using fluorescence microscopy. Thus, this method can detect both the presence and the distribution of molecules of interest in the virion population. Single-virion analysis was first developed to study HIV-1 RNA genome packaging. In this assay, HIV-1 unspliced RNA is labeled with a fluorescently tagged RNA-binding protein (protein A) and some of the Gag proteins are labeled with a different fluorescent protein (protein B). Using fluorescence microscopy, HIV-1 particles can be identified by the fluorescent protein B signal and the presence of unspliced HIV-1 RNA can be identified by the fluorescent protein A signal. Therefore, the proportions of particles that contain unspliced RNA can be determined by the fraction of Gag particles that also have a colocalized RNA signal. By tagging the molecule of interest with fluorescent proteins, single-virion analysis can be easily adapted to study the incorporation of other viral or host cell molecules into particles. Indeed, this method has been adapted to examine the proportion of HIV-1 particles that contain APOBEC3 proteins and the fraction of particles that contain a modified Gag protein. Therefore, single-virion analysis is a flexible method to study the nucleic acid and protein content of HIV-1 particles.


Sujet(s)
VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Microscopie de fluorescence , ARN viral , Virion , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Virion/métabolisme , Microscopie de fluorescence/méthodes , Humains , ARN viral/génétique , ARN viral/métabolisme , Assemblage viral , Réplication virale , Infections à VIH/virologie , Infections à VIH/métabolisme
14.
Methods Mol Biol ; 2807: 113-125, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743224

RÉSUMÉ

The postnuclear entry steps of HIV-1 involve reverse transcription, uncoating, and integration into the host genome. The differential regulation of these steps has a significant impact on HIV overall replication, including integration site selection and viral gene expression. Recently, another important phenomenon has been uncovered as part of HIV interplay with the nuclear environment, specifically involving the cleavage and polyadenylation specific factor 6 (CPSF6) protein. This phenomenon is the formation of nuclear HIV-induced membraneless organelles (HIV-1 MLOs). In this article, we will describe the methods used to assess the composition and liquid-liquid phase separation (LLPS) properties of these organelles using fluorescence microscopy. The study of HIV-1 MLOs represents a new frontier that may reveal previously unknown key players in the fate of HIV-infected cells.


Sujet(s)
Noyau de la cellule , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Microscopie de fluorescence , Humains , Microscopie de fluorescence/méthodes , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Noyau de la cellule/métabolisme , Organites/métabolisme , Infections à VIH/virologie , Infections à VIH/métabolisme
15.
Methods Mol Biol ; 2807: 127-138, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743225

RÉSUMÉ

The initial stages of HIV-1 infection involve the transport of the viral core into the nuclear compartment. The presence of the HIV-1 core in the nucleus triggers the translocation of CPSF6/CPSF5 from paraspeckles into nuclear speckles, forming puncta-like structures. While this phenomenon is well-documented, the efficiency of CPSF6 translocation to nuclear speckles upon HIV-1 infection varies depending on the type of cell used. In some human cell lines, only 1-2% of the cells translocate CPSF6 to nuclear speckles when exposed to a 95% infection rate. To address the issue that only 1-2% of cells translocate CPSF6 to nuclear speckles when a 95% infection rate is achieved, we screened several human cell lines and identified a human a cell line in which approximately 85% of the cells translocate CPSF6 to nuclear speckles when 95% infection rate is achieved. This cellular system has enabled the development of a robust fluorescence microscopy method to quantify the translocation of CPSF6 into nuclear speckles following HIV-1 infection. This assay holds the potential to support studies aimed at understanding the role of CPSF6 translocation to nuclear speckles in HIV-1 infection. Additionally, since the translocation of CPSF6 into nuclear speckles depends on the physical presence of the viral core in the nucleus, our method also serves as a reporter of HIV-1 nuclear import.


Sujet(s)
Transport nucléaire actif , Noyau de la cellule , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Facteurs de clivage et de polyadénylation de l'ARN messager , Humains , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/métabolisme , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Facteurs de clivage et de polyadénylation de l'ARN messager/métabolisme , Facteurs de clivage et de polyadénylation de l'ARN messager/génétique , Noyau de la cellule/métabolisme , Lignée cellulaire , Infections à VIH/virologie , Infections à VIH/métabolisme
16.
Methods Mol Biol ; 2807: 153-161, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743227

RÉSUMÉ

Recent evidence has shown that uncoating and reverse transcription precede nuclear import. These recent breakthroughs have been made possible through the development of innovative biochemical and imaging techniques. This method outlines the biochemical assay used for detecting the presence of the HIV-1 core in the nuclear compartment. In this procedure, human cells are infected with HIV-1NL4-3, with or without the inclusion of PF74, a small molecule that inhibits core entry into the nuclear compartment. Subsequently, cells are separated into cytosolic and nuclear fractions. To assess whether the capsid protein has reached the nuclear compartment, cytosolic and nuclear fractions are subjected to Western blot analysis, utilizing antibodies specific to the HIV-1 capsid protein p24. To validate the true origin of these fractions, Western blot analysis employing antibodies against cytosolic and nuclear markers are also performed. In summary, this assay provides a reliable and efficient means to detect the presence of the HIV-1 capsid protein in the nucleus during infection under various conditions.


Sujet(s)
Capside , Noyau de la cellule , Infections à VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Humains , Noyau de la cellule/métabolisme , Infections à VIH/virologie , Infections à VIH/métabolisme , Capside/métabolisme , Protéine de capside p24 du VIH/métabolisme , Protéine de capside p24 du VIH/analyse , Protéines de capside/métabolisme , Technique de Western/méthodes , Phénylalanine/métabolisme , Phénylalanine/analogues et dérivés , Lignée cellulaire
17.
Int J Mol Sci ; 25(9)2024 Apr 25.
Article de Anglais | MEDLINE | ID: mdl-38731913

RÉSUMÉ

Despite combined antiretroviral therapy (cART) limiting HIV replication to undetectable levels in the blood, people living with HIV continue to experience HIV-associated neurocognitive disorder (HAND). HAND is associated with neurocognitive impairment, including motor impairment, and memory loss. HIV has been detected in the brain within 8 days of estimated exposure and the mechanisms for this early entry are being actively studied. Once having entered into the central nervous system (CNS), HIV degrades the blood-brain barrier through the production of its gp120 and Tat proteins. These proteins are directly toxic to endothelial cells and neurons, and propagate inflammatory cytokines by the activation of immune cells and dysregulation of tight junction proteins. The BBB breakdown is associated with the progression of neurocognitive disease. One of the main hurdles for treatment for HAND is the latent pool of cells, which are insensitive to cART and prolong inflammation by harboring the provirus in long-lived cells that can reactivate, causing damage. Multiple strategies are being studied to combat the latent pool and HAND; however, clinically, these approaches have been insufficient and require further revisions. The goal of this paper is to aggregate the known mechanisms and challenges associated with HAND.


Sujet(s)
Barrière hémato-encéphalique , Humains , Barrière hémato-encéphalique/métabolisme , Barrière hémato-encéphalique/anatomopathologie , Infections à VIH/complications , Infections à VIH/virologie , Infections à VIH/anatomopathologie , Infections à VIH/métabolisme , Démence associée au SIDA/métabolisme , Démence associée au SIDA/anatomopathologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Troubles neurocognitifs/étiologie , Troubles neurocognitifs/métabolisme , Troubles neurocognitifs/anatomopathologie , Animaux
18.
J Immunol Res ; 2024: 6343757, 2024.
Article de Anglais | MEDLINE | ID: mdl-38715844

RÉSUMÉ

This study aims to explore the influence of coinfection with HCV and HIV on hepatic fibrosis. A coculture system was set up to actively replicate both viruses, incorporating CD4 T lymphocytes (Jurkat), hepatic stellate cells (LX-2), and hepatocytes (Huh7.5). LX-2 cells' susceptibility to HIV infection was assessed through measurements of HIV receptor expression, exposure to cell-free virus, and cell-to-cell contact with HIV-infected Jurkat cells. The study evaluated profibrotic parameters, including programed cell death, ROS imbalance, cytokines (IL-6, TGF-ß, and TNF-α), and extracellular matrix components (collagen, α-SMA, and MMP-9). The impact of HCV infection on LX-2/HIV-Jurkat was examined using soluble factors released from HCV-infected hepatocytes. Despite LX-2 cells being nonsusceptible to direct HIV infection, bystander effects were observed, leading to increased oxidative stress and dysregulated profibrotic cytokine release. Coculture with HIV-infected Jurkat cells intensified hepatic fibrosis, redox imbalance, expression of profibrotic cytokines, and extracellular matrix production. Conversely, HCV-infected Huh7.5 cells exhibited elevated profibrotic gene transcriptions but without measurable effects on the LX-2/HIV-Jurkat coculture. This study highlights how HIV-infected lymphocytes worsen hepatic fibrosis during HCV/HIV coinfection. They increase oxidative stress, profibrotic cytokine levels, and extracellular matrix production in hepatic stellate cells through direct contact and soluble factors. These insights offer valuable potential therapies for coinfected individuals.


Sujet(s)
Effet bystander , Techniques de coculture , Co-infection , Cytokines , Infections à VIH , Hepacivirus , Cellules étoilées du foie , Hépatite C , Cirrhose du foie , Humains , Cellules étoilées du foie/métabolisme , Infections à VIH/complications , Infections à VIH/métabolisme , Infections à VIH/virologie , Infections à VIH/immunologie , Hepacivirus/physiologie , Hépatite C/métabolisme , Hépatite C/virologie , Hépatite C/complications , Hépatite C/immunologie , Cellules Jurkat , Cirrhose du foie/métabolisme , Cirrhose du foie/anatomopathologie , Cirrhose du foie/virologie , Cirrhose du foie/étiologie , Cytokines/métabolisme , Hépatocytes/métabolisme , Hépatocytes/virologie , VIH (Virus de l'Immunodéficience Humaine)/physiologie , Stress oxydatif , Communication cellulaire , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Matrice extracellulaire/métabolisme
19.
Methods Mol Biol ; 2807: 141-151, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743226

RÉSUMÉ

To integrate with host chromatin and establish a productive infection, HIV-1 must translocate the viral Ribonucleoprotein (RNP) complex through the nuclear pore complex (NPC). Current assay to measure HIV-1 nuclear import relies on a transient byproduct of HIV-1 integration failure called 2-LTR circles. However, 2-LTR circles require complete or near-complete reverse transcription and association with the non-homologous end joining (NHEJ) machinery in the nucleus, which can complicate interpretation of 2-LTR circle formation as a measure of nuclear import kinetics. Here, we describe an approach to measure nuclear import of infectious HIV-1 particles. This involves chemically induced dimerization of Nup62, a central FG containing nucleoporin. Using this technique, nuclear import of infectious particles can be monitored in both primary and cell culture models. In response to host factor depletion or restriction factors, changes in HIV-1 nuclear import can be effectively measured using the nuclear import kinetics (NIK) assay.


Sujet(s)
Transport nucléaire actif , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Complexe protéique du pore nucléaire , Pore nucléaire , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/métabolisme , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Humains , Pore nucléaire/métabolisme , Complexe protéique du pore nucléaire/métabolisme , Cinétique , Noyau de la cellule/métabolisme , Infections à VIH/virologie , Infections à VIH/métabolisme , Intégration virale
20.
Viruses ; 16(5)2024 04 25.
Article de Anglais | MEDLINE | ID: mdl-38793552

RÉSUMÉ

The HIV-1 capsid (CA) protein forms the outer shell of the viral core that is released into the cytoplasm upon infection. CA binds various cellular proteins, including CPSF6, that direct HIV-1 integration into speckle-associated domains in host chromatin. Upon HIV-1 infection, CPSF6 forms puncta in the nucleus. Here, we characterised these CPSF6 puncta further in HeLa cells, T-cells and macrophages and confirmed that integration and reverse transcription are not required for puncta formation. Indeed, we found that puncta formed very rapidly after infection, correlating with the time that CA entered the nucleus. In aphidicolin-treated HeLa cells and macrophages, puncta were detected for the length of the experiment, suggesting that puncta are only lost upon cell division. CA still co-localised with CPSF6 puncta at the latest time points, considerably after the peak of reverse transcription and integration. Intriguingly, the number of puncta induced in macrophages did not correlate with the MOI or the total number of nuclear speckles present in each cell, suggesting that CA/CPSF6 is only directed to a few nuclear speckles. Furthermore, we found that CPSF6 already co-localised with nuclear speckles in uninfected T-cells, suggesting that HIV-1 promotes a natural behaviour of CPSF6.


Sujet(s)
VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Macrophages , Lymphocytes T , Facteurs de clivage et de polyadénylation de l'ARN messager , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Humains , Facteurs de clivage et de polyadénylation de l'ARN messager/métabolisme , Facteurs de clivage et de polyadénylation de l'ARN messager/génétique , Lymphocytes T/virologie , Lymphocytes T/métabolisme , Cellules HeLa , Macrophages/virologie , Macrophages/métabolisme , Intégration virale , Noyau de la cellule/métabolisme , Protéines de capside/métabolisme , Protéines de capside/génétique , Infections à VIH/virologie , Infections à VIH/métabolisme , Capside/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...